Can I read Anticoagulant and Non-anticoagulant Therapy in Thrombotic Antiphospholipid Syndrome: Old Drugs and New Treatment Targets on EtoBox?

Anticoagulant and Non-anticoagulant Therapy in Thrombotic Antiphospholipid Syndrome: Old Drugs and New Treatment Targets by Guillermo Ruiz-Irastorza; Maria G Tektonidou; Munther Khamashta is a Medicine article available to read on EtoBox.

What is Anticoagulant and Non-anticoagulant Therapy in Thrombotic Antiphospholipid Syndrome: Old Drugs and New Treatment Targets about?

## Abstract In this review, we discuss the current evidence on classic and newer oral anticoagulant therapy, older drugs such as HCQ and statins, and new potential treatment targets in APS. Vitamin K antagonists (VKAs) remain the cornerstone treatment for thrombotic events in APS. In patients fulfilling criteria for definite APS presenting with a first venous thrombosis, treatment with VKAs with a target international normalized ratio (INR) 2.0–3.0 is recommended. In patients with arterial thrombosis, treatment with VKA with target INR 2.0–3.0 or 3.0–4.0 is recommended by recent guidelines, considering the individual’s bleeding and thrombosis recurrence risk. A combination of VKAs and low-dose aspirin (75–100 mg/daily) may also be considered. According to available evidence direct oral anticoagulants should be avoided in patients with arterial thrombosis and/or those with triple aPL positivity. Adjunctive treatment with HCQ and/or statins can be considered, especially in anticoagulation treatment–refractory APS. Potential targeted treatments in APS include B-cell targeting, complement inhibition, mammalian target of rapamycin inhibition, IFN targeting, adenosine receptors agonists,

Who reads Anticoagulant and Non-anticoagulant Therapy in Thrombotic Antiphospholipid Syndrome: Old Drugs and New Treatment Targets?

Author

Guillermo Ruiz-Irastorza; Maria G Tektonidou; Munther Khamashta

Publisher

Oxford University Press (OUP)

Published

2024

Language

EN

Field

Medicine (Health Sciences)